Criteo (NASDAQ:CRTO – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Stifel Nicolaus in a research note issued to investors on Thursday,Benzinga reports. They currently ...

Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...

Stifel analysts adjusted their outlook on Equifax stock (NYSE:EFX), reducing the price target to $281.00 from a previous $284.00, while still endorsing the stock with a Buy rating. The revision comes ...

Eagle Financial Services, Inc. (OTCQX: EFSI) (the "Company"), parent company of Bank of Clarke, today announced the pricing of its previously announced underwritten public offering of 1,562,500 shares ...

an affiliate of Stifel Financial Corp., a global diversified financial services firm. The credit facility with Stifel Bank will provide financing for working capital and growth capital, enabling ...

In a report released today, Devin Ryan from JMP Securities reiterated a Buy rating on Stifel Financial (SF – Research Report), with a price ...

Investing.com -- Stifel has raised its price target for EssilorLuxottica SA (EPA:ESLX) from €207 to €241, citing significant potential from its partnership with Meta Platforms (NASDAQ ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport ... Leading companies in the sector maintain strong financial metrics, with healthy EBITDA ...

The financial services landscape is undergoing a seismic transformation. To thrive, institutions will have to offer more than traditional banking products like accounts or payments and instead ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...